Francesco Granata, M.D. Joins Board of Prismic Pharmaceuticals

        Francesco Granata, M.D. Joins Board of Prismic Pharmaceuticals

  PR Newswire

  SCOTTSDALE, Arizona, Dec. 3, 2013

SCOTTSDALE, Arizona, Dec. 3, 2013 /PRNewswire/ --Prismic Pharmaceuticals,
Inc., a Scottsdale, Arizona-based, commercial-stage pharmaceutical company
focused on prescription Medical Foods, today announced the election of
Francesco Granata, M.D., to its Board of Directors.

Dr. Granata is currently Executive in Residence at Warburg Pincus, a leading
private equity firm focused on growth investing. He is an accomplished
healthcare executive with more than 35 years of experience in the
international pharmaceutical and biotechnology industries. Before joining
Warburg Pincus, Dr. Granata held senior management positions at Pfizer, where
he was President of the Northern Europe region; Schering-Plough, where he
served as Group Vice President and President for the Europe and Canada region;
and most recently at Biogen Idec Inc., where he was Executive Vice President
of Global Commercial Operations, with responsibilityfor worldwide Commercial
Operations and Medical Affairs. Dr. Granata is also a Board Member of
Circassia, a UK-based specialty Biopharmaceutical company and Italfarmaco, one
of Italy's leading international pharmaceutical groups.

"Francesco Granata has had an exceptionally successful career and brings a
wealth of healthcare experience and strategic vision to our Board of
Directors," commented Peter Moriarty, Chairman and CEO of Prismic. "Prior to
joining the pharmaceutical industry, Francesco practiced as a physician and
surgeon, specializing in Cardiology. He has also been Chairman of the
European Committee of the Pharmaceutical Research and Manufacturers
Association of America and Co-Chairman of the Heads of Europe Committee of the
European Federation of Pharmaceutical Industries and Associations. We are
honored that he has accepted the invitation to join our Board. We are
confident of the contribution he will make in helping the Board to guide
Prismic's continuing path to commercial success and increased value for our
shareholders."

"Prismic has an extremely interesting and innovative portfolio of
patent-protected products," stated Dr. Granata. "I believe that the company
has identified products and market opportunities that are medically important
as well as commercially very attractive. Prismic has the choice of exploiting
those opportunities alone or in partnership with other commercial entities in
the United States and Internationally. I look forward to working with my
fellow Board members to help Management drive optimum value for our
shareholders."

About Prismic Pharmaceuticals, Inc. Prismic Pharmaceuticals, Inc., is a
privately held, commercial-stage pharmaceutical company focused on the
development and marketing of prescription Medical Foods for the clinical
dietary management of the metabolic processes associated with many of the
disorders associated with the aging population, particularly where
inflammation is involved. The company, founded in 2011, is headquartered in
Scottsdale, Arizona, with offices in Boston, USA, and London, England. Contact
+1-480-422-1810 or visit www.PrismicPharma.com .

INFORMATION CONTACT Peter MoriartyTel: +1-480-422-1810

Website: http://www.prismicpharma.com